Filing summary
Filing identity: The supplied filing is Zafgen, Inc.’s Form 10-Q for the quarter ended September 30, 2015, filed November 13, 2015. This does not match the request metadata naming Larimar Therapeutics, Inc.; verify the issuer before relying on this summary. Amounts below are in U.S. dollars; financial statement figures are converted from thousands to millions unless otherwise stated.
Business context and reporting period
Zafgen was a development-stage biopharmaceutical company focused on obesity and metabolic disorders. Its lead candidate, beloranib, was in clinical development for Prader-Willi syndrome (PWS), hypothalamic injury-associated obesity and severe obesity. ZGN-839 and other MetAP2 inhibitors were earlier-stage programs. The company had not generated revenue and reported results for the three and nine months ended September 30, 2015, with comparisons to the same periods in 2014.
Financial results and liquidity
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $14.2m | $12.1m | $36.9m | $20.0m |
| General and administrative expense | $5.5m | $2.3m | $13.7m | $4.8m |
| Total operating expenses | $19.7m | $14.4m | $50.6m | $24.9m |
| Net loss | $19.9m | $14.7m | $51.1m | $25.5m |
| Net loss per share, basic and diluted | $0.73 | $0.65 | $1.92 | $2.97 |
| Cash used in operating activities | Not separately reported for quarter | $41.6m | $16.5m |
- Margins: No revenue was reported, so revenue-based margins are not meaningful.
- Cash and investments: At September 30, cash and cash equivalents were $38.8m and marketable securities were $165.2m, totaling approximately $204.0m, versus $115.5m at December 31, 2014. Current assets were $206.1m and current liabilities $13.6m.
- Debt: Notes payable had $6.8m principal outstanding; balance-sheet carrying amounts were $2.9m current and $4.2m long-term, net of discount and including final-payment accretion. The credit facility’s effective annual interest rate was approximately 14%; principal payments were scheduled through 2017.
- Equity and funding: The January 2015 follow-on offering generated approximately $130.0m net proceeds. Stockholders’ equity was $189.7m at September 30, 2015, compared with $104.4m at year-end 2014.
- Cash flows: Nine-month investing cash outflow was $107.6m, largely reflecting purchases of marketable securities net of maturities. Financing provided $129.8m, principally from the follow-on offering.
Material changes versus prior comparable periods
- Nine-month operating expenses rose $25.7m and net loss increased $25.6m year over year. R&D rose $16.9m, including higher beloranib trial activity and spending on ZGN-839 and second-generation inhibitors; G&A rose $8.8m, reflecting hiring, stock-based compensation, public-company costs and PWS commercial-readiness work.
- Q3 net loss increased $5.2m year over year. Higher R&D and G&A expenses were partly offset by improved net other expense.
- Cash and marketable securities increased substantially from year-end, primarily following the January offering. Cash and cash equivalents alone declined by $19.3m during the first nine months as funds were deployed into marketable securities and operations.
- Weighted-average shares rose to 26.6m for the nine-month period from 8.6m in 2014, reflecting the IPO and subsequent equity issuances; consequently, the reported per-share loss was lower despite a larger total loss.
Outlook, risks and unusual items
- Beloranib safety and regulatory status: The company reported learning in October 2015 that a patient who died in its Phase 3 PWS trial had received beloranib. The death certificate cited respiratory failure resulting from pulmonary emboli; the company stated that a causal relationship to beloranib was unknown, while the clinical investigator characterized the event as possibly related. The FDA placed the beloranib IND on partial clinical hold on October 15, 2015, requiring additional safety measures.
- Trial plans: Zafgen elected to close the randomized portions of the Phase 3 ZAF-311 PWS trial and Phase 2b ZAF-203 trial and proceed with safety and efficacy analysis. Other future beloranib trials, including planned Phase 3 ZAF-312, were on hold pending FDA review. The company expected to proceed to data analysis in Q1 2016, subject to FDA acceptance of its statistical analysis plan. The ZAF-311 open-label extension continued on a patient-by-patient basis subject to screening and re-consent.
- Runway and funding: Management estimated that September 30 cash, cash equivalents and marketable securities would fund operating expenses and capital needs for at least 18 months. This estimate depended on assumptions that could prove incorrect. The company expected rising expenses and said additional financing would ultimately be required; equity funding could dilute holders, while debt or collaborations could impose restrictions or require relinquishing rights.
- Operating outlook: Zafgen expected significant expenses and increasing operating losses for the foreseeable future and did not expect near-term product revenue. Development, regulatory, clinical-trial and manufacturing outcomes remained uncertain.
- Legal contingency: A purported stockholder filed a securities class action on October 21, 2015, alleging misleading statements and omissions concerning beloranib trials. The company said it could not assess the likelihood of loss or estimate a potential loss range because the case was at an early stage.
- Other exposures: The company reported no off-balance-sheet arrangements. It had licensing-related potential milestone obligations of up to $12.25m for pre-commercial milestones and $12.5m for commercialization milestones, plus potential royalties. It also disclosed unhedged Australian-dollar exposure and no material changes to contractual obligations outside the ordinary course of business.
Most important facts for investors to verify
- Confirm the filing belongs to the intended issuer: the source identifies Zafgen, Inc., not Larimar Therapeutics, Inc.
- Check subsequent FDA and trial developments, including the partial hold, required safety measures, trial data, and whether planned beloranib studies could resume.
- Assess the patient death and other thrombotic events in the context of the complete safety data and regulatory conclusions; this filing states causality was not established.
- Evaluate the assumptions behind management’s estimate of at least 18 months of funding runway, given rising cash burn and the need for future capital.
- Monitor the securities lawsuit and any change in the company’s ability to estimate or accrue a loss.